NCT01256372

An Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

An Explorative Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Trial of Two Dosing Regimens of AP214 for the Prevention of Kidney Injury in Patients Undergoing Cardiac Surgery

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 77 (actual)
• Sponsor: Action Pharma A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study investigates the effect of two dose-levels of AP214 on the prevention of (acute) kidney injury after cardiac surgery.

Conditions

• Cardiac Surgery
• Coronary Artery Bypass
• Aortic Aneurysm
• Valve Surgery
• Kidney Diseases

Interventions

Type	Name	Description
DRUG	AP214	AP214
DRUG	Placebo	Placebo; intravenous infusion

Timeline

• Start date: 2010-10-01
• Primary completion: 2011-06-01
• Completion: 2011-08-01
• First posted: 2010-12-08
• Last updated: 2012-03-15

Locations

1 site across 1 country: Denmark